<DOC>
	<DOCNO>NCT00002332</DOCNO>
	<brief_summary>To evaluate mechanism whereby thymopentin appear retard progressive immune suppression attributable HIV infection .</brief_summary>
	<brief_title>A Study Timunox ( Thymopentin ) HIV-Infected Patients Receiving Other Anti-HIV Drugs</brief_title>
	<detailed_description>Patients randomize receive subcutaneous thymopentin placebo thrice weekly 4 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Thymopentin</mesh_term>
	<criteria>Inclusion Criteria Patients must : Asymptomatic minimally symptomatic HIV infection ( evidence AIDS ) . CD4 count &lt; = 400 cells/mm3 within 6 week prior study entry ( CD4 count change 100 400 cells/mm3 per amendment ) . Tolerated current nucleoside analog antiretroviral treatment least 4 week prior study entry . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Known hypersensitivity thymopentin component formulation . Significant chronic underlie medical illness would impede study participation . Grade 2 high peripheral neuropathy relate nucleoside analog antiretroviral treatment . Concurrent Medication : Excluded : Any antiretroviral agent zidovudine , didanosine , dideoxycytidine . HIV vaccines investigational nonFDA approve medication immunomodulatory experimental therapy within 30 day prior study entry . Patients follow prior condition exclude : Abnormal chest xray consistent active opportunistic infection within 6 week prior study entry . Prior Medication : Excluded : Any prior antiretroviral agent zidovudine , didanosine , dideoxycytidine within 30 day prior study entry . Required : Current nucleoside analog antiretroviral treatment . Required : Nucleoside analog antiretroviral treatment least 4 week prior study entry . Significant active alcohol drug abuse sufficient prevent study compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 1995</verification_date>
	<keyword>Thymopentin</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>